Home
Applications
Indications
Business
EpiSwitch
®
Products
EpiSwitch
®
Checkpoint Inhibitor Response Test
EpiSwitch
®
COVID-19 Severity Test
EpiSwitch
®
Explorer Array Kit
EPISWITCH
®
ANALYTICAL PORTAL
EpiSwitch
®
Service
Investors
Investors Overview
Results and Presentations
Share Price Information
Regulatory News
Board & Governance
Key Corporate Documents
AIM Rule 26
Email Alerts
Investor Contacts
News
About Us
History
Board of Directors
Management Team
Scientific Advisory Panel
Values
Careers
Contact Us
Fcg Receptor Targeting Reduces Bone Disease in a Pre-clinical Model Of Multiple Myeloma.
Home
Publications
OBD presents at the 57th American Society of Hematology Meeting in Orlando, FL its collaborative work with Scottish Centre for Immunobiology, University of Glasgow.
Fcg Receptor Targeting Reduces Bone Disease in a Pre-clinical Model Of Multiple Myeloma.
Fcg Receptor Targeting Reduces Bone Disease in a Pre-clinical Model Of Multiple Myeloma.
Privacy Preference Center
Privacy Preferences
